The international model and diabetes advocate on career, self-confidence and being the change she wants to see.

Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...

Sales: The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and ...

Q4 2024 Earnings Call Transcript February 13, 2025 DexCom, Inc. misses on earnings expectations. Reported EPS is $0.45 EPS, expectations were $0.4792. Operator: Thank you for standing by. My name is ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

Additionally, regulatory progress with the 15-day G7 CGM could provide a long-term boost. While challenges such as competitive pressures and channel mix shifts remain, DexCom appears well ...

Its innovative CGM systems, like the G6 and the newer G7, offer real-time glucose level tracking, giving users actionable insights. The company has been concentrating on product development ...

DexCom, Inc. DXCM is scheduled to release fourth-quarter 2024 results on Feb. 13, after the closing bell. In the last ...

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...

Stratos Wealth Partners LTD. purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 2,583 shares of the medical device ...